Results 161 to 170 of about 266,977 (390)

Angiotensin II induces peroxisome proliferator‐activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation [PDF]

, 2005
Yi Zhao, Anna Foryst‐Ludwig, Dennis Bruemmer, Juraj Čulman, Michael Bäder, Thomas Unger, Ulrich Kintscher   +6 more
openalex   +1 more source

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky, Stefan Engeli, Stefanie M. Bode‐Böger, Felix Koop, Martin Schulze Westhoff, Sebastian Schröder, Carsten Schumacher, Thorben Pape, Dirk O. Stichtenoth, Johannes Heck   +9 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Potential nephroprotective effects of angiotensin II type 2 receptor agonist Compound 21 in renal ischemia-reperfusion injury. [PDF]

J Med Life, 2023
Kadhim LF, Gany SN, Qassam H, Hadi NR, Kadhim S.   +4 more
europepmc   +1 more source

The angiotensin II type 2 receptor and the gastrointestinal tract

Journal of the Renin-Angiotensin-Aldosterone System, 2009
The renin-angiotensin system (RAS) is well known for its vital involvement in body fluid homeostasis and circulation. However, very little research has been devoted to the impact of this regulatory system on the gastrointestinal (GI) system. This is surprising because the GI tract is fundamental for the intake and excretion of fluid and electrolytes ...
openaire   +2 more sources

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Stimulation of angiotensin II type 2 receptor attenuates organ injury in rats with polymicrobial sepsis. [PDF]

J Chin Med Assoc, 2023
Shih CC, Chen SJ, Chang WK, Tsai HJ, Huang HC, Wu CC, Tsao CM.   +6 more
europepmc   +1 more source

Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction [PDF]

, 2017
Angiotensin II (All) has been implicated as an important factor in the pathophysiology of heart diseases. Following the recent identification of two subtypes of the All receptor in cardiac tissue of animals, we investigated the possible occurrence of ...
Burkart, F., de Gasparo, M., Eberhard, M., Erne, P., Graedel, E., Rogg, H., Stulz, P.   +6 more
core  

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source